177 related articles for article (PubMed ID: 15784311)
1. Identification of a novel antifungal nonapeptide generated by combinatorial approach.
Kumar M; Chaturvedi AK; Kavishwar A; Shukla PK; Kesarwani AP; Kundu B
Int J Antimicrob Agents; 2005 Apr; 25(4):313-20. PubMed ID: 15784311
[TBL] [Abstract][Full Text] [Related]
2. A novel dodecapeptide from a combinatorial synthetic library exhibits potent antifungal activity and synergy with standard antimycotic agents.
Duggineni S; Srivastava G; Kundu B; Kumar M; Chaturvedi AK; Shukla PK
Int J Antimicrob Agents; 2007 Jan; 29(1):73-8. PubMed ID: 17156978
[TBL] [Abstract][Full Text] [Related]
3. Identification of novel antifungal nonapeptides through the screening of combinatorial peptide libraries based on a hexapeptide motif.
Kundu B; Srinivasan T; Kesarwani AP; Kavishwar A; Raghuwanshi SK; Batra S; Shukla PK
Bioorg Med Chem Lett; 2002 Jun; 12(11):1473-6. PubMed ID: 12031322
[TBL] [Abstract][Full Text] [Related]
4. Combinatorial approach to lead optimization of a novel hexapeptide with antifungal activity.
Kundu B; Rastogi SK; Batra S; Raghuwanshi SK; Shukla PK
Bioorg Med Chem Lett; 2000 Aug; 10(16):1779-81. PubMed ID: 10969966
[TBL] [Abstract][Full Text] [Related]
5. Antifungal activity of artemisinin derivatives.
Galal AM; Ross SA; Jacob M; ElSohly MA
J Nat Prod; 2005 Aug; 68(8):1274-6. PubMed ID: 16124777
[TBL] [Abstract][Full Text] [Related]
6. Structure-antifungal activity relationship of His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2 and analogues.
Masman MF; Somlai C; Garibotto FM; Rodríguez AM; de la Iglesia A; Zacchino SA; Penke B; Enriz RD
Bioorg Med Chem; 2008 Apr; 16(8):4347-58. PubMed ID: 18346897
[TBL] [Abstract][Full Text] [Related]
7. In vitro synergic antifungal effect of MUC7 12-mer with histatin-5 12-mer or miconazole.
Wei GX; Bobek LA
J Antimicrob Chemother; 2004 May; 53(5):750-8. PubMed ID: 15073161
[TBL] [Abstract][Full Text] [Related]
8. Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans.
Schwarz P; Janbon G; Dromer F; Lortholary O; Dannaoui E
Antimicrob Agents Chemother; 2007 Jan; 51(1):383-5. PubMed ID: 17043122
[TBL] [Abstract][Full Text] [Related]
9. In vitro susceptibilities of Malaysian clinical isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii to five antifungal drugs.
Tay ST; Tanty Haryanty T; Ng KP; Rohani MY; Hamimah H
Mycoses; 2006 Jul; 49(4):324-30. PubMed ID: 16784448
[TBL] [Abstract][Full Text] [Related]
10. Fungicidal effect of three new synthetic cationic peptides against Candida albicans.
Nikawa H; Fukushima H; Makihira S; Hamada T; Samaranayake LP
Oral Dis; 2004 Jul; 10(4):221-8. PubMed ID: 15196144
[TBL] [Abstract][Full Text] [Related]
11. In vitro susceptibility of Cryptococcus neoformans clinical isolates from Egypt to seven antifungal drugs.
Abdel-Salam HA
Mycoses; 2005 Sep; 48(5):327-32. PubMed ID: 16115103
[TBL] [Abstract][Full Text] [Related]
12. Potent in vitro synergism of fluconazole and berberine chloride against clinical isolates of Candida albicans resistant to fluconazole.
Quan H; Cao YY; Xu Z; Zhao JX; Gao PH; Qin XF; Jiang YY
Antimicrob Agents Chemother; 2006 Mar; 50(3):1096-9. PubMed ID: 16495278
[TBL] [Abstract][Full Text] [Related]
13. In vitro interaction between azoles and cyclosporin A against clinical isolates of Candida albicans determined by the chequerboard method and time-kill curves.
Li Y; Sun S; Guo Q; Ma L; Shi C; Su L; Li H
J Antimicrob Chemother; 2008 Mar; 61(3):577-85. PubMed ID: 18194958
[TBL] [Abstract][Full Text] [Related]
14. In vitro antifungal susceptibility of clinical isolates of Candida spp. obtained from patients with different predisposing factors to candidosis.
Pinto PM; Weikert-Oliveira Rde C; Lyon JP; Cury VF; Arantes RR; Koga-Ito CY; Resende MA
Microbiol Res; 2008; 163(5):579-85. PubMed ID: 16962755
[TBL] [Abstract][Full Text] [Related]
15. Reassessment of the in vitro synergistic effect of fluconazole with the non-steroidal anti-inflammatory agent ibuprofen against Candida albicans.
Arai R; Sugita T; Nishikawa A
Mycoses; 2005 Jan; 48(1):38-41. PubMed ID: 15679664
[TBL] [Abstract][Full Text] [Related]
16. Bulky 1,4-benzoxazine derivatives with antifungal activity.
Fringuelli R; Giacchè N; Milanese L; Cenci E; Macchiarulo A; Vecchiarelli A; Costantino G; Schiaffella F
Bioorg Med Chem; 2009 Jun; 17(11):3838-46. PubMed ID: 19433362
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo antifungal activity of the combination methylpartricin-5-fluorocytosine.
Strippoli V; Torosantucci A; Simonetti N
Chemioterapia; 1984 Apr; 3(2):119-25. PubMed ID: 6398120
[TBL] [Abstract][Full Text] [Related]
18. Surface-active fungicidal D-peptide inhibitors of the plasma membrane proton pump that block azole resistance.
Monk BC; Niimi K; Lin S; Knight A; Kardos TB; Cannon RD; Parshot R; King A; Lun D; Harding DR
Antimicrob Agents Chemother; 2005 Jan; 49(1):57-70. PubMed ID: 15616276
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and conformational analysis of His-Phe-Arg-Trp-NH2 and analogues with antifungal properties.
Masman MF; Rodríguez AM; Svetaz L; Zacchino SA; Somlai C; Csizmadia IG; Penke B; Enriz RD
Bioorg Med Chem; 2006 Nov; 14(22):7604-14. PubMed ID: 16926096
[TBL] [Abstract][Full Text] [Related]
20. In vitro susceptibility of oral Candida to seven antifungal agents.
Kuriyama T; Williams DW; Bagg J; Coulter WA; Ready D; Lewis MA
Oral Microbiol Immunol; 2005 Dec; 20(6):349-53. PubMed ID: 16238594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
